Pulnovo Medical Secures Substantial Series C Financing
Pulnovo Medical, an innovative company that specializes in medical devices for pulmonary hypertension (PH) and heart failure (HF), recently closed a significant round of Series C financing, amounting to nearly $100 million. This financing was co-led by Qiming Venture Partners along with support from existing investor Lilly Asia Ventures. Notable investors OrbiMed and Gaorong Capital also participated on a super pro-rata basis, reflecting their ongoing trust in Pulnovo's vision and product offerings.
Fund Use for Expanding Global Reach
The completion of this financing round allows Pulnovo Medical to enhance its global clinical trials and expand its international business operations. The considerable interest in this round, with oversubscription by two times, highlights the confidence that leading institutions have in the company’s strategic objectives and technical advancements.
Innovations in Heart Failure Therapy
Founded in 2013, Pulnovo Medical has built a reputation as a pioneering player in the medtech industry, particularly recognized for its commitment to scientific innovation. The firm’s core focus is on providing superior therapeutic solutions aimed at improving outcomes for patients suffering from heart failure at various stages.
One of Pulnovo Medical’s flagship products is the PADN (Pulmonary Artery Denervation) technology. This groundbreaking minimally invasive treatment effectively targets the pulmonary vascular endothelial sympathetic nerve using radiofrequency ablation, significantly lowering pulmonary artery pressure and helping to slow disease progression. This novel approach offers new hope to patients facing the severe challenges of PH, where traditional treatment options are limited.
Acknowledgment of Clinical Advancements
The PADN technology received FDA Breakthrough Device designation in 2021 for its potential in Groups I, II, and IV of PH. Moreover, the product was included in crucial guidelines published by the European Society of Cardiology and the European Respiratory Society in 2022. By 2023, Pulnovo Medical also obtained the Humanitarian Use Exemption Device designation for Group I PH. The RF catheter and generator earned market approval in China by the end of 2023, marking a significant milestone as a commercially available intervention device in the global landscape of medical technology.
Additionally, the company’s accessory product, the 9F sheath, received FDA clearance in 2024, further solidifying its commitment to innovation and excellence in the healthcare sector.
Leadership Insights on Growth Initiatives
Cynthia Chen, the Chairlady, Executive Chairwoman, and President of Pulnovo Medical, expressed enthusiasm about the recent financing, indicating that it would empower the company to launch two upcoming trials under FDA regulations focusing on Groups I and II PH. Under her leadership, the firm has evolved from a research-based organization into a structured global entity with offices propped up in the United States, Singapore, and Hong Kong, along with several cities across the Chinese mainland including Beijing and Shanghai.
Investor Confidence and Global Trials
William Hu, Managing Partner of Qiming Venture Partners, commended Pulnovo Medical for its impressive breakthroughs in interventional treatments for PH and HF. He highlighted that the company's PADN technology is now commercially active in regions including Chinese Mainland, Hong Kong, and Macau. Looking ahead to 2024, multicenter trials are set to commence across several countries, including Portugal, Serbia, Georgia, and parts of Southeast Asia. The recognition of PADN as an FDA Breakthrough Device, coupled with ongoing global clinical trials, validates the leadership and clinical relevance of this innovative approach. Qiming Venture Partners expresses its unwavering support for Pulnovo Medical's ambitious international expansion, aiming to deliver enhanced healthcare solutions and new hope to patients globally.
Frequently Asked Questions
What is the significance of the Series C financing?
The Series C financing allows Pulnovo Medical to enhance its clinical trials, expand internationally, and support strategic initiatives aimed at improving healthcare solutions.
What innovative technology is Pulnovo Medical known for?
Pulnovo Medical is known for its PADN technology, which is a minimally invasive treatment for pulmonary hypertension aimed at improving patient outcomes.
How has Pulnovo Medical been recognized in the medical community?
Pulnovo Medical has received FDA Breakthrough Device designation and is noted in international guidelines by the European Society of Cardiology and the European Respiratory Society.
What markets are being targeted by Pulnovo Medical for their clinical trials?
The upcoming clinical trials will be conducted in various regions, including Portugal, Serbia, Georgia, and Southeast Asia in 2024.
Who leads Pulnovo Medical's strategic direction?
Cynthia Chen serves as the Chairlady and has successfully guided the company from its laboratory roots to a structured global firm.
